1. Home
  2. NX vs PHAT Comparison

NX vs PHAT Comparison

Compare NX & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NX
  • PHAT
  • Stock Information
  • Founded
  • NX 1927
  • PHAT 2018
  • Country
  • NX United States
  • PHAT United States
  • Employees
  • NX N/A
  • PHAT N/A
  • Industry
  • NX Metal Fabrications
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • NX Industrials
  • PHAT Health Care
  • Exchange
  • NX Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • NX 852.8M
  • PHAT 716.5M
  • IPO Year
  • NX N/A
  • PHAT 2019
  • Fundamental
  • Price
  • NX $22.49
  • PHAT $11.91
  • Analyst Decision
  • NX Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • NX 1
  • PHAT 5
  • Target Price
  • NX $38.00
  • PHAT $16.40
  • AVG Volume (30 Days)
  • NX 399.8K
  • PHAT 1.1M
  • Earning Date
  • NX 09-04-2025
  • PHAT 08-07-2025
  • Dividend Yield
  • NX 1.41%
  • PHAT N/A
  • EPS Growth
  • NX N/A
  • PHAT N/A
  • EPS
  • NX 0.39
  • PHAT N/A
  • Revenue
  • NX $1,625,028,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • NX $49.00
  • PHAT $194.40
  • Revenue Next Year
  • NX $2.99
  • PHAT $103.23
  • P/E Ratio
  • NX $57.68
  • PHAT N/A
  • Revenue Growth
  • NX 47.66
  • PHAT 1049.82
  • 52 Week Low
  • NX $15.30
  • PHAT $2.21
  • 52 Week High
  • NX $32.23
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • NX 64.48
  • PHAT 75.25
  • Support Level
  • NX $20.32
  • PHAT $9.82
  • Resistance Level
  • NX $22.08
  • PHAT $11.19
  • Average True Range (ATR)
  • NX 0.79
  • PHAT 0.71
  • MACD
  • NX 0.15
  • PHAT 0.17
  • Stochastic Oscillator
  • NX 91.17
  • PHAT 94.07

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: